You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Precision Medicine for Treatment of Rare Diseases in Cardiology

  • Authors: Martha Grogan, MD, MS; Vallerie McLaughlin, MD; Omar Abou Ezzeddine, MDCM, MS; Lisa Cooper Hudgins, MD; Martha Kingman, DNP, APRN, FNP-C; Ahmad Masri, MD, MS; Jose Nativi-Nicolau, MD, MS, FACC, FHFSA; Brett W. Sperry, MD
  • CME / ABIM MOC / CE Released: 12/28/2021
  • Valid for credit through: 12/28/2022
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, pulmonologists, primary care physicians (PCPs), endocrinologists, nurses, and radiologists who care for patients with rare diseases in cardiology.

The goal of this activity is to raise the suspicion of the diagnosis of rare disease in cardiology by educating the learners about the signs, symptoms, diagnosis, and individualized treatment strategies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical signs and symptoms to raise suspicion of rare cardiac conditions
    • Current and emerging treatment options for rare cardiac conditions
  • Have greater competence related to
    • Diagnosis of rare cardiac conditions
    • Use of individualized treatment strategies for patients with rare cardiac conditions to optimize outcomes


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Co-Chairs

  • Martha Grogan, MD, MS

    Assistant Professor of Medicine
    Director
    Cardiac Amyloid Clinic
    Department of Cardiovascular Medicine
    Mayo Clinic
    Rochester, Minnesota

    Disclosures

    Disclosure: Martha Grogan, MD, MS, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Akcea; Alnylam; Eidos; Pfizer; Prothena

  • Vallerie McLaughlin, MD

    Professor of Cardiovascular Medicine
    Director, Pulmonary Hypertension Program
    University of Michigan
    Ann Arbor, Michigan

    Disclosures

    Disclosure: Vallerie McLaughlin, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acceleron; Actelion; Aerovate; Altavant; Bayer; Caremark; Eicos; Gossamer Bio; Merck; United Therapeutics
    Received grants for clinical research from: Acceleron; Actelion; Reata; Sunovion; United Therapeutics

Faculty

  • Omar Abou Ezzeddine, MDCM, MS

    Assistant Professor of Medicine
    Mayo Clinic College of Medicine and Science
    Director
    Cardiac Sarcoidosis Clinic, Division of Circulatory Failure, Department of Cardiovascular Medicine
    Rochester, Minnesota

    Disclosures

    Disclosure: Omar Abou Ezzeddine, MDCM, MS, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: Pfizer

  • Lisa Cooper Hudgins, MD

    Director, Pediatric Comprehensive Lipid Control Center, The Rogosin Institute
    Associate Professor of Pediatrics, Weill Cornell Medicine
    Associate Professor of Pediatrics in Medicine, Weill Cornell Medicine
    Associate Attending Physician, New York-Presbyterian Hospital
    New York, New York

    Disclosures

    Disclosure: Lisa Cooper Hudgins, MD, has disclosed no relevant financial relationships.

  • Martha Kingman, DNP, APRN, FNP-C

    Nurse Practitioner
    Pulmonary Services, Heart and Lung Center
    University of Texas Southwestern Medical Center
    Dallas, Texas

    Disclosures

    Disclosure: Martha Kingman, DNP, APRN, FNP-C, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acceleron; Bayer; Johnson & Johnson; United Therapeutics

  • Ahmad Masri, MD, MS

    Assistant Professor of Medicine
    Division of Cardiovascular Medicine
    Oregon State School of Medicine
    Portland, Oregon

    Disclosures

    Disclosure: Ahmad Masri, MD, MS, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam; Bristol Myers Squibb; Cytokinetics; Eidos; Ionis/Akcea; Pfizer
    Received grants for clinical research from: Akcea; Pfizer; Ultromics

  • Jose Nativi-Nicolau, MD, MS, FACC, FHFSA

    Associate Professor of Medicine
    University of Utah Health
    Heart Failure and Transplant Cardiology
    Cardiology Director, Utah Amyloidosis Program
    Cardiology Director, Cardiovascular Intensive Care Unit
    Salt Lake City, Utah

    Disclosures

    Disclosure: Jose Nativi-Nicolau, MD, MS, FACC, FHFSA, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea/Ionis; Alnylam; Pfizer
    Received grants for clinical research from: Akcea/Ionis; Alnylam; Eidos; Pfizer

  • Brett W. Sperry, MD

    Cardiologist
    Saint Luke's Mid America Heart Institute
    Kansas City, Missouri

    Disclosures

    Disclosure: Brett W. Sperry, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam; Pfizer
    Served as a speaker or a member of a speakers bureau for: Pfizer

Editors

  • Meghan Coulehan, MPH

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Meghan Coulehan, MPH, has disclosed no relevant financial relationships.

  • Cheryl Perkins, MD, RPh

    Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: Cheryl Perkins, MD, RPh, has disclosed no relevant financial relationships. 

CME Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC  

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.  

Nurse Planner

  • Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC  

    Disclosures

    Disclosure: Leigh Schmidt, MSN, RN, CMSRN, CNE, CHCP, has disclosed no relevant financial relationships.  

All other faculty, planners and non-faculty contributors involved in the planning, development, editing, and review of the content have no relevant financial relationships with ineligible companies.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds: Roche Diagnostics Inc


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Precision Medicine for Treatment of Rare Diseases in Cardiology

Authors: Martha Grogan, MD, MS; Vallerie McLaughlin, MD; Omar Abou Ezzeddine, MDCM, MS; Lisa Cooper Hudgins, MD; Martha Kingman, DNP, APRN, FNP-C; Ahmad Masri, MD, MS; Jose Nativi-Nicolau, MD, MS, FACC, FHFSA; Brett W. Sperry, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/28/2021

Valid for credit through: 12/28/2022

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

PAH Present and Future: Current Strategies and Emerging Approaches

Dr Martha Kingman discusses current and emerging approaches for PAH.
Martha Kingman, DNP, APRN, FNP-C

Hope for HCM: What We Know About Cardiac Myosin Inhibition

Dr Ahmad Masri discusses what we know about cardiac myosin inhibition.
Ahmad Masri, MD, MS

Challenges in Diagnosis and Approaches to Improve ATTR Cardiomyopathy Diagnosis

Dr Brett Sperry addresses the challenges in ATTR diagnosis and strategies to improve diagnosis.
Brett W. Sperry, MD

New and Emerging Treatment Options for ATTR

Dr Nativi-Nicolau shares new and emerging treatment options for ATTR.
Jose Nativi-Nicolau, MD, MS, FACC, FHFSA

Advances in HoFH: Present and Emerging Treatment Options

Dr Lisa Hudgins discusses advances in treatment options for HoFH.
Lisa Cooper Hudgins, MD

Sarcoidosis, the Great Masquerader: Challenges in Diagnosis and Treatment

Dr Omar Ezzeddine reviews challenges in diagnosis and treating sarcoidosis.
Omar Abou Ezzeddine, MDCM, MS

Assessment Survey

Before you begin, please take this brief survey.